|
Authors
|
Paper name
|
Published in
|
Year
|
|
Reynolds CP, Schindler P, Jones D, Gentile J, Proffitt R, Einhorn P
|
Comparison of 13-cis- retinoic acid to trans-retinoic acid using human neuroblastoma cell lines
|
Advances in Neuroblastoma Research 4, Evans A, Biedler JL, Brodeur G, D'Angio GJ, Nakagawara A (eds.), New York: John Wiley & Sons, 237-244
|
1994
|
|
Keshelava N, Seeger RC, Reynolds CP
|
Drug resistance phenotype of neuroblastoma cell lines established at diagnosis and at relapse after induction chemotherapy or bone marrow transplantation
|
European J Cancer33:2002-2006
|
1997
|
|
Anderson CP, Tsai JM, Chan WW, Liu RM, Forman HJ, Reynolds CP
|
Buthionine sulfoximine (BSO) is cytotoxic via apoptosis and synergistically enhances the activity of melphalan (L-PAM) in human neuroblastoma cell lines
|
European J Cancer 33:2016-2019
|
1997
|
|
Keshelava N, Seeger RC, Groshen S, Reynolds CP
|
Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy
|
Cancer Research 58:5396-5405
|
1998
|
|
Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds G P
|
Depletion of Glutathione (GSH) by buthionine sulfoximine (BSO) is cytotoxic for human neuroblastoma cell lines via apoptosis
|
Experimental Cell Research246:183-192
|
1999
|
|
Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP
|
N-(4-hydroxypheynl)retinamide increases ceramide and reactive oxygen species and induces mixed apoptosis/necrosis in neuroblastoma cell lines
|
J Natl Cancer Inst 91:1138-1146
|
1999
|
|
Keshelava N, Groshen S, Reynolds CP
|
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines
|
Cancer Chemotherapy and Pharmacology45:1-8
|
2000
|
|
Chen RL, Reynolds CP, Seeger RC, Cabot MC, Reynolds CP
|
Neutrophils are cytotoxic and growth inhibiting for neuroblastoma cells with anti-GD2 antibody but without cytotoxicity can be growth stimulating
|
Clinical Immunol Immunother48:603-612
|
2000
|
|
Maurer BJ, Cabot MC, Reynolds CP
|
Synergism of N-(4-hydroxyphenyl)retinamide cytotoxicity by modulators of ceramide metabolism in solid tumor cell lines
|
J Natl Cancer Inst 92:1897-1908
|
2000
|
|
Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ
|
Retinoic-acid resistant neuroblastoma cell lines show altered myc regulation and high sensitivity to fenretinide
|
Medical Pediatric Oncology35:597-602
|
2000
|
|
Keshelava N, Zuo JJ, Chen P, Waidyaratine SN, Luna MC, Gomer CJ, Triche CJ, Reynolds CP
|
Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines
|
Cancer Research 61:6185-6193
|
2001
|
|
Anderson CP, Seeger RC, Satake N, Meek WE, Keshelava N, Bailey HH, Monforte-Munoz HL, Reynolds CP
|
Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line
|
J Pediat Hematol Oncol 23:500-505
|
2001
|
|
Metelitsa LS, Gillies SD, Super M, Shimada H, Reynolds CP, Seeger RC
|
Enhanced expression and activation of Mac-1(CD11b/CD18) by an anti-GD2/GM-CSF fusion protein increases neutrophil antibody dependent cellular cytotoxicity
|
Blood 99:4166-4173
|
2002
|
|
O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ
|
N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes
|
Leukemia 16:902-910
|
2002
|
|
Anderson C, Reynolds CP
|
Cytotoxicity of buthionine sulfoximine (BSO) and melphalan/BSO in combination for neuroblastoma cell lines derived after myeloablative therapy
|
Bone Marrow Transplantation30:135-140
|
2002
|
|
Peter J. Houghton, Peter C. Adamson, Susan Blaney, Howard A. Fine, Richard Gorlick, Michelle Haber, Lee Helman, Steve Hirschfeld, Melinda G. Hollingshead, Mark A. Israel, Richard B. Lock, John M. Maris, Glenn Merlino, Wendy Patterson, C. Patrick Reynolds, Kevin Shannon, Alice Yu, John Yu, and Malcolm A. Smith
|
Testing of New Agents in Childhood Cancer Preclinical Models : Meeting Summary
|
Clinical Cancer Research8:3646-3657
|
2002
|
|
Bo Yang, Nino Keshelava, Clarke P. Anderson, and C. Patrick Reynolds
|
Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia Is Reversed by the Bioreductive Agent Tirapazamine
|
Cancer Research 63:1520-1526
|
2003
|
|
Nino Keshelava, Denice Tsao-Wei, and C. Patrick Reynolds
|
Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p531
|
Clinical Cancer Research9:3492-3502
|
2003
|
|
Grigoryan, R., Keshelava, N., Anderson, C., and Reynolds, C. P.
|
In vitro testing of chemosensitivity in physiological hypoxia.
|
Methods Mol.Med., 110: 87-100
|
2005
|
|
Reynolds, C. P. and Maurer, B. J.
|
Evaluating response to antineoplastic drug combinations in tissue culture models.
|
Methods Mol.Med., 110: 173-183
|
2005
|
|
Yang, B. and Reynolds, C. P.
|
Tirapazamine cytotoxicity for neuroblastoma is p53 dependent.
|
Clin.Cancer Res., 11: 2774-2780
|
2005
|
|
Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Tony Ng T, Reynolds CP, Triche TJ, Sorensen PHB
|
E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase.
|
Cancer Research, 67: 3094-3105
|
2007
|
|
Houghton PJ, Morton CL, Tucker C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Wu J, Smith MA
|
Stage 1 testing of the proteasome inhibitor bortezomib by the Pediatric Preclinical Testing Program.
|
Pediatric Blood & Cancer,(In Press).
|
2007
|
|
Keshelava N, Davicioni E, Zesheng Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP
|
Inhibition of histone deacetylase (HDAC) 1, a drug target identified by expression profiling, sensitizes multi-drug-resistant neuroblastoma cell lines to cytotoxic agents.
|
J National Cancer Institute, 99:1107-19
|
2007
|
|
Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA
|
Initial testing (Stage 1) of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program.
|
Pediatric Blood & Cancer.,(In Press)
|
2007
|
|
Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned T, Lock RB, Reynolds CP
|
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
|
Blood, 110:205-2066
|
2007
|
|
Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB
|
Initial testing (Stage 1) of cisplatin by the Pediatric Preclinical Testing Program.
|
Pediatric Blood & Cancer,(In Press)
|
2007
|
|
Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA
|
Initial testing of dasatinib by the Pediatric Preclinical Testing Program.
|
Pediatric Blood & Cancer,(In Press)
|
2007
|
|
Reynolds CP, Kang MH, Keshelava N, Mauer BJ
|
Assessing combinations of cytotoxic agents using leukemia cell lines.
|
Current Drug Targets,8:765-771
|
2007
|